文献速递类风湿关节炎脊柱关节炎

丹麦全国802例炎性关节炎患者从原研英夫利西单抗非医疗切换至生物类似药CT-P13的1年临床结局:DANBIO登记研究

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
PubMed 文献 · Ann Rheum Dis · 2017-05-04

基于DANBIO登记,丹麦对802例RA、PsA和AxSpA患者将原研英夫利西单抗(INX)非医疗切换为生物类似药CT-P13,切换前后3个月疾病活动度相似;粗1年CT-P13保留率84.1%与历史INX队列86.2%相似(p=0.22),但调整后绝对保留率83.4%略低于86.8%(p=0.03)。

要点

  • 非医疗切换前后3个月疾病活动度无显著变化。
  • 粗1年CT-P13保留率84.1%与历史INX队列86.2%相似。
  • 调整后1年保留率CT-P13略低于历史INX队列。

核心结论

  • 在802例经INX治疗中位超过6年的关节炎患者中,全国性非医疗切换至CT-P13对疾病活动度无负面影响。
  • 调整后1年CT-P13保留率略低于历史队列中的INX。

研究设计与样本

  • 基于DANBIO登记的前瞻性队列研究,纳入802例RA、PsA和AxSpA患者。
  • 比较切换前后3个月疾病活动度及随时间变化,并与历史INX治疗队列比较粗率和调整后保留率。

主要发现

  • 802例患者中RA 403例、PsA 120例、AxSpA 279例;女性51%,年龄中位数55岁(IQR 44-66)。
  • 随访413天(IQR 339-442),既往INX治疗时长中位数6.8年(IQR 4.3-9.5)。
  • 切换前后3个月疾病活动度相似。
  • 粗1年CT-P13保留率84.1%(95%CI 81.3-86.5)与历史INX队列86.2%(95%CI 84.0-88.0)相似,p=0.22。
  • 调整后绝对保留率CT-P13为83.4%(95%CI 80.8-86.2),历史INX为86.8%(95%CI 84.8-88.8),p=0.03。

关键数值与推荐

  • 疾病活动度变化:RA/PsA采用ΔDAS28≥1.2定义 flare,AxSpA采用ΔASDAS≥1.3定义 flare。
  • 既往INX治疗时长>5年的患者CT-P13保留时间更长。

临床怎么用

  • 支持在长期INX治疗稳定的关节炎患者中实施非医疗切换至CT-P13,短期疾病活动度无恶化。
  • 切换后需关注保留率略低于原研药的可能性,尤其调整混杂因素后。

局限性

  • 历史队列比较可能存在时代偏倚和未测量混杂。
  • 观察性登记研究,非随机对照设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: According to guidelines, a nationwide non-medical switch from originator (INX, Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). We investigated disease activity before/after switching and retention rates in the DANBIO registry. METHODS: Disease activities 3 months before and after switch and changes over time were calculated. Flare was defined as change in 28 Joint Disease Activity Score (∆DAS28) ≥1.2 (RA/PsA) or Ankylosing Spondylitis Disease Activity Score (∆ASDAS) ≥1.3 (AxSpA). Crude and adjusted retention rates were compared with a historic cohort of INX-treated patients. RESULTS: Eight hundred and two patients switched (403 RA/120 PsA/279 AxSpA; 51% women, age (median (IQR): 55 (44-66)) years). Follow-up was 413 (339-442) days. Prior INX treatment duration was 6.8 (4.3-9.5) years. Disease activities were similar 3 months before/after switch. Crude 1-year CT-P13 retention rate (84.1 (95% CI 81.3 to 86.5)) was similar to the historic IFX cohort (86.2 (95% CI 84.0 to 88.0), p=0.22). The adjusted absolute retention rates were 83.4 (95% CI 80.8 to 86.2) and 86.8% (95% CI 84.8 to 88.8), respectively (p=0.03). In total 132 patients withdrew (lack of effect: 71/132=54%, adverse events: 37/132=28%). Patients with previous INX treatment duration >5 years had longer CT-P13 retention. CONCLUSION: In 802 arthritis patients treated with INX for median >6 years, a nationwide non-medical switch to CT-P13 had no negative impact on disease activity. Adjusted 1-year CT-P13 retention rate was slightly lower than for INX in a historic cohort.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Glintborg B, Sørensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017. PMID: 28473425. doi:10.1136/annrheumdis-2016-210742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。